MedTrace Logo

Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

NCT05379348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1423

Last updated 2026-03-30

No results posted yet for this study

Summary

The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.

Conditions

  • Alzheimer Disease

Interventions

OTHER

Cognitive Assessment

Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.

Sponsors & Collaborators

  • Davos Alzheimer's Collaborative

    collaborator UNKNOWN

  • AdventHealth Translational Research Institute

    lead OTHER

Principal Investigators

  • Steven Smith, MD · Study PI

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2025-08-05
Completion
2025-08-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05379348 on ClinicalTrials.gov